Title
Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer's disease.

Permalink
https://escholarship.org/uc/item/8v0012vn

Journal
Brain : a journal of neurology, 143(1)

ISSN
0006-8950

Authors
Younan, Diana
Petkus, Andrew J
Widaman, Keith F
et al.

Publication Date
2020

DOI
10.1093/brain/awz348

Peer reviewed
Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer’s disease

Journal: Brain

Manuscript ID: BRAIN-2019-00160.R2

Manuscript Type: Original Article

Date Submitted by the Author: n/a

Complete List of Authors: Younan, Diana; University of Southern California, Petkus, Andrew; University of Southern California Widaman, Keith; University of California Riverside Wang, Xinhui; University of Southern California Casanova, Ramon; Wake Forest University School of Medicine, Dept Biostatistical Sciences Espeland, Mark; Wake Forest University School of Medicine, Dept of Biostatistical Sciences Gatz, Margaret; University of Southern California, Department of Psychology; Karolinska Institutet, Department of Medical Epidemiology and Biostatistics Henderson, Victor; Stanford University, Health Research & Policy (Epidemiology) and Neurology & Neurological Sciences; Manson, JoAnn; Brigham and Women’s Hospital, Harvard Medical School Rapp, Steve; Wake Forest University School of Medicine, Psychiatry; Wake Forest University School of Medicine, Brain Tumor Center of Excellence Sachs, Bonnie; Wake Forest University School of Medicine Serre, Marc; University of North Carolina at Chapel Hill, Gillings School of Global Health Gaussoin, Sarah; Wake Forest University School of Medicine Barnard, Ryan; Wake Forest University School of Medicine Saldana, Santiago ; Wake Forest University School of Medicine Vizuete, William; University of North Carolina at Chapel Hill Beavers, Daniel; Wake Forest University School of Medicine Salinas, Joel; Massachusetts General Hospital, Harvard Medical School Chui, Helena; University of Southern California, Department of Neurology Resnick, Susan; National Insitute on Aging, Laboratory of Behavioral Neuroscience Shumaker, Sally; Wake Forest University School of Medicine Chen, Jiu-Chiuan ; University of Southern California

Subject category: Dementia

To search keyword list, use whole or part words followed by an *: Cognitive ageing < DEMENTIA, Dementia: epidemiology < DEMENTIA, Dementia: biomarkers < DEMENTIA, Memory < DEMENTIA, Neuroinflammation < MULTIPLE SCLEROSIS AND NEUROINFLAMMATION, Neurodegeneration: other < NEURODEGENERATION: CELLULAR AND
Full title: Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer’s disease

Short running title: Neurotoxic particles on brain aging continuum


Affiliations

University of Southern California
2001 N Soto St, Los Angeles, CA 90032, USA
(Emails: dyounan@usc.edu; petkus@usc.edu; xinhuiwa@gmail.com; gatz@usc.edu; helena.chui@med.usc.edu; jcchen@usc.edu)

University of California at Riverside
900 University Ave, Riverside, CA 92521
(Email: keith.widaman@ucr.edu)

Wake Forest School of Medicine
475 Vine St, Winston-Salem, NC 27101, USA
(Emails: casanova@wakehealth.edu; mespelan@wakehealth.edu; srapp@wakehealth.edu; bsachs@wakehealth.edu; sgaussoi@wakehealth.edu; rybarnar@wakehealth.edu; ssaldana@wakehealth.edu; db beavers@wakehealth.edu; ss humake@wakehealth.edu)

Stanford University
259 Campus Dr, Stanford, CA 94305, USA
(Email: vhenderson@stanford.edu)

Brigham and Women’s Hospital, Harvard Medical School
75 Francis St, Boston, MA 02115, USA
(Email: jmanson@rics.bwh.harvard.edu)

University of North Carolina
250 E Franklin S, Chapel Hill, NC 27514, USA
(Emails: marc_serre@unc.edu; airquality@unc.edu)

Massachusetts General Hospital, Harvard Medical School,
55 Fruit St, Boston, MA 02114, USA
(Email: joel.salinas@mgh.harvard.edu)

Laboratory of Behavioral Neuroscience, National Institute on Aging
251 Bayview Boulevard, Suite 100, Baltimore, MD 21224, USA
(Email: resnicks@mail.nih.gov)
Authors contributed equally to this work.

*Joint corresponding authors:
Diana Younan
University of Southern California
2001 N Soto St, Los Angeles, CA, 90032
Tel: +1-323-442-8271
Email: dyounan@usc.edu

Jiu-Chiuan Chen
Email: jcchen@usc.edu
Abstract

Evidence suggests PM$_{2.5}$ (particulate matter with aerodynamic diameter <2.5 μm) exposure may increase the risk for Alzheimer’s disease and related dementias. Whether PM$_{2.5}$ alters brain structure and accelerates the preclinical neuropsychological processes remains unknown. Early decline of episodic memory is detectable in preclinical Alzheimer’s disease. Therefore, we conducted a longitudinal study to examine whether PM$_{2.5}$ affects the episodic memory decline, and also explored the potential mediating role of increased neuroanatomic risk of Alzheimer’s disease associated with exposure. Participants included older women (n = 998; aged 73-87) enrolled in both the Women’s Health Initiative Study of Cognitive Aging and the Women’s Health Initiative Memory Study-MRI, with annual (1999-2010) episodic memory assessment by the California Verbal Learning Test, including measures of immediate free recall/new learning (List A Trials 1-3; List B) and delayed free recall (short- and long-delay), and up to two brain scans (MRI-1: 2005-6; MRI-2: 2009-10). Women were assigned Alzheimer’s disease pattern similarity scores (a brain-MRI measured neuroanatomical risk for Alzheimer’s disease), developed by supervised machine learning and validated with data from the Alzheimer’s disease Neuroimaging Initiative. Based on residential histories and environmental data on air monitoring and simulated atmospheric chemistry, we employed a spatiotemporal model to estimate 3-year average PM$_{2.5}$ exposure preceding MRI-1. In multilevel structural equation models, PM$_{2.5}$ was associated with greater declines in immediate recall and new learning, but no association was found with decline in delayed-recall or composite scores. For each inter-quartile increment (2.81 μg/m$^3$) of PM$_{2.5}$, the annual decline rate was significantly accelerated by 19.3% (95% CI = 1.9%, 36.2%) for Trials 1-3 and 14.8% (4.4%, 24.9%) for List B performance, adjusting for multiple potential confounders. Long-term PM$_{2.5}$ exposure was associated with increased Alzheimer’s disease pattern similarity scores, which accounted for 22.6% (95% CI: 1% - 68.9%) and 10.7% (95% CI: 1.0% - 30.3%) of the total adverse PM$_{2.5}$ effects on Trials 1-3 and List B, respectively. The observed associations remained after excluding incident cases of dementia and stroke during the follow-up, or further adjusting for small-vessel ischemic disease volumes. Our findings illustrate the continuum of PM$_{2.5}$ neurotoxicity that contributes to early decline of immediate free recall/new learning at the preclinical stage, which is mediated by progressive atrophy of gray matter indicative of increased Alzheimer’s disease risk, independent of cerebrovascular damage.
Keywords: fine particulate matter; air pollution; episodic memory; Alzheimer’s disease; neuroimaging; epidemiologic studies

Abbreviations:
AD-PS, Alzheimer’s Disease Pattern Similarity
ADNI, Alzheimer’s Disease Neuroimaging Initiative
AQS, Air Quality System
BME, Bayesian Maximum Entropy
CA, cornu ammonis
CVLT, California Verbal Learning Test
EPA, Environmental Protection Agency
FLAIR, fluid-attenuated inversion recovery
PM, particulate matter
PM$_{2.5}$, particulate matter with aerodynamic diameter $<2.5$ μm
SEM, structural equation model
SVID, small vessel ischemic disease
WHI, Women’s Health Initiative
WHIMS, Women’s Health Initiative Memory Study
WHIMS-MRI, Women’s Health Initiative Memory Study of Magnetic Resonance Imaging
WHISCA, Women’s Health Initiative Study of Cognitive Aging
**Introduction**

Exposure to ambient air pollution represents a novel environmental risk factor of accelerated brain aging (Underwood, 2017). In recent years, a growing number of epidemiologic studies have shown that fine particulate matter (PM with aerodynamic diameter <2.5 μm; PM$_{2.5}$) may increase the risk of dementia, including Alzheimer’s disease (Jung et al., 2015; Cacciottolo et al., 2017; Chen et al., 2017; Carey et al., 2018; Oudin et al., 2018). Toxicopathological studies suggest air pollution accelerates amyloid-β accumulation in mice (Bhatt et al., 2015; Cacciottolo et al., 2017) and neurofibrillary tangles in canines (Calderón-Garcidueñas et al., 2003). Despite the increasing evidence supporting the neurological effects of PM$_{2.5}$ on Alzheimer’s disease and related dementias, definitive conclusions on the causal association cannot be made, because the underlying mechanisms remain unclear (The Lancet Neurology, 2018).

Declines in verbal episodic memory (e.g. the ability to remember details, with context, from daily and remote experiences) are the hallmark symptom of Alzheimer’s disease detectable in the preclinical stage (Gallagher and Koh, 2011). Episodic memory is comprised of distinct cognitive processes such as encoding the target information (learning) and subsequently retrieving the target information, each involving complex neural systems (Dickerson and Eichenbaum, 2010). Several animal studies have demonstrated that inhaled PM$_{2.5}$ exposures affect various neural systems thought to underlie these episodic memory processes (Fonken et al., 2011; Cheng et al., 2017; Ku et al., 2017; Liu et al., 2018). Few longitudinal epidemiological studies examined the association between PM$_{2.5}$ and episodic memory (Weuve et al., 2012; Tonne et al., 2014; Wurth et al., 2018), and the majority of these studies utilized composite scores with mixed results. Importantly, no previous studies had directly linked air pollution exposures with cognitive decline and altered brain structure predictive of dementia risk. Therefore, we conducted a longitudinal study to examine the association between long-term exposure to PM$_{2.5}$ and decline in episodic memory (immediate recall/new learning; delayed-recall), and to investigate the extent to which the putative adverse PM$_{2.5}$ effects on declines were mediated by changes in neuroanatomic structure indicative of increased Alzheimer’s disease risk.

**Materials and methods**
Study design and population

We conducted a prospective cohort study that included community-dwelling women who were initially enrolled in the Women’s Health Initiative (WHI) Memory Study and subsequently participated in both the WHI Study of Cognitive Aging (WHISCA) and the WHI Memory Study of Magnetic Resonance Imaging (WHIMS-MRI) ancillary studies (Resnick et al., 2009; Coker et al., 2014). WHIMS participants (N=7479) were postmenopausal women aged 65 years and older who were recruited from 1996 through 1999 across 48 states and free of dementia as determined by standardized study protocols, described elsewhere (Shumaker et al., 2004) (Supplementary Methods). A subsample of cognitively-intact WHIMS participants (N=2,304) were followed in WHISCA with annual neurocognitive testing during the period of 1999-2010. Between April 2005 and January 2006, WHIMS participants (N=1,403) across 14 (of 38) active WHIMS sites were enrolled in the WHIMS-MRI study, yielding 1,365 scans that met quality control standards. A total of 1,050 women participated in both WHISCA and WHIMS-MRI. For the present study, we excluded subjects with missing data on relevant covariates, resulting in a final analytic sample of 998 women (Fig. 1). A total of 531 women underwent a second MRI between the years of 2009 and 2010.

Measures of episodic memory

Episodic memory was assessed using the California Verbal Learning Test (CVLT), focusing on immediate recall, new learning, and delayed-recall (Fridlund and Delis, 1987). Participants were read a 16-item list of words (List A) from four semantically-related categories. Each time the list was read the participant was instructed to immediately repeat back as many words as she could remember. In WHISCA, participants were administered only three learning trials. After completion of the List A trials, a single learning/recall trial of the alternate List B items was administered. Promptly after the List B “interference” trial, the participants were asked to freely recall all words from List A (short-delay free recall). After an approximate 20-minute delay, the free recall trials were repeated (long-delay free recall). For the outcome variables, we used the total number of correct responses on each measure: 1) List A learning trials 1-3; 2) List B learning/recall trial; 3) List A short-delay free recall; and 4) List A long-delay free recall. Each measure was z-score standardized based on the mean and standard deviation (SD) at the initial
WHISCA assessment. The z-scores for these three List A measures were averaged to create the composite score of CVLT performance.

**WHIMS-MRI acquisition and processing**

MRI scans were performed using standardized scan acquisition protocols developed by the MRI Quality Control Center (Resnick *et al.*, 2009). Standard T1-, T2-, proton density-weighted, and fluid-attenuated inversion recovery (FLAIR) scans were acquired with a 22 cm field of view and a matrix of 256×256 in 1.5T scanners at fourteen sites. Included were oblique axial spin density/T2-weighted spin echo (TR:3200 ms, TE=30/120 ms, slice thickness=3 mm), fluid-attenuated inversion recovery (FLAIR) T2-weighted spin echo (TR=8000 ms, TI=2000 ms, TE=100 ms, slice thickness=3 mm), and oblique axial three-dimensional T1-weighted gradient echo (flip angle=30 degrees, TR=21 ms, TE=8 ms, slice thickness=1.5 mm) images from the vertex to the skull base parallel to the anterior commissure–posterior commissure plane.

As part of the WHIMS-MRI protocol developed by the reading center, a brain lesion segmentation algorithm was applied to T1-, T2-, and FLAIR scans to segment small-vessel ischemic disease (SVID) (Lao *et al.*, 2008). By combining the tissue segmentation and lesion segmentation algorithm, each voxel was classified as either normal (not SVID-affect) or abnormal (SVID-affected). Normal-appearing brain volume and SVID volumes in gray and white matter regions were calculated, then abnormal brain volumes in these regions were combined to classify total SVID volume.

**Joint brain MRI data processing across two populations**

We used high-dimensional warping methods to process structural brain MRI images (T1-weighted) from WHIMS-MRI participants. More details about the MRI data processing across dataset can be found in other reports (Tustison *et al.*, 2014; Casanova *et al.*, 2018). Here, we briefly describe the main steps. The Advanced Normalization Tools software was used to align the brain images from the WHIMS-MRI and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) into a common template. The images were submitted to N4 bias field correction (Tustison *et al.*, 2010), brain extraction, segmentation (Avants *et al.*, 2011), template construction and normalization. A script consisting of six stages (brain extraction; template
registration; tissue segmentation; improved template registration; cortical thickness registration; and quality control and summary measurements) was used to generate the template based on a randomly selected sample of 50 cognitively normal Caucasian women (55-90 years old; mean age: 76.8) from ADNI. The brain MRI images (n=2,436) from both WHIMS-MRI and ADNI were segmented and warped to the template.

**Alzheimer’s disease pattern similarity score**

The Alzheimer’s Disease Pattern Similarity (AD-PS) score was derived using a high-dimensional (voxel-wise) supervised machine learning algorithm based on the elastic net regularized logistic regression (EN-RLR) to analyze structural brain MRI data pattern at voxel level (Friedman et al., 2010), comparing Alzheimer’s disease cases and cognitively normal individuals (Casanova et al., 2011). The EN-RLR is known to produce sparse models (Zou and Hastie, 2005) which translates in the context of our neuroimaging application into a variable selection mechanism able to identify voxels or brain areas relevant for classification that we call discriminative maps. The score formally is the class-conditional probability of membership to the Alzheimer’s disease group as modeled by the EN-RLR model when discriminating cognitively normal from Alzheimer’s disease participants in ADNI (Casanova et al., 2013), interpreted as a measure of similarity of the brain spatial patterns found in one individual’s MRI to those found in individuals diagnosed with Alzheimer’s disease.

The AD-PS scores of WHIMS MRI participants were derived by two steps: 1) estimating the EN-RLR classifier based on gray matter probability maps from cognitively-normal and Alzheimer’s disease participants in ADNI; and 2) providing baseline and follow-up WHIMS-MRI gray matter probability maps as input to the EN-RLR classifier to generate the gray matter AD-PS score for WHIMS-MRI participants. The discriminative maps derived in step 1 revealed gray matter atrophies in areas (e.g., amygdala, hippocampus, para-hippocampal gyrus, thalamus, inferior temporal lobe areas and midbrain) where Alzheimer’s disease neuropathologies are thought to first emerge (Brettschneider et al., 2015). We had previously reported both cross-sectional and longitudinal relationships of higher AD-PS scores with increased age, poorer cognitive performance, and greater SVID volume in WHIMS-MRI participants (Casanova et al., 2018). In a longitudinal analysis of global cognitive trajectories over 10 years, the groups of
older women with relatively lower AD-PS scores were considered more resilient to cognitive decline (Espeland et al., 2018). Our empirical data also showed that an SD (=0.23) increase in AD-PS scores over a 5-year period was associated with a 122% increase in dementia risk (hazard ratio=2.22; 95% CI: 1.80, 2.75) defined by DSM-IV criteria, adjusting for socio-demographics, region, lifestyle factors, and clinical characteristics.

**Air pollution exposure assessment**

Residential addresses of WHIMS participants were prospectively collected during each clinic visit and updated at least biannually. Residential histories were then sent to a single vendor that followed standardized protocols for geocoding (Whitsel et al., 2004). Ambient concentration of PM$_{2.5}$ was estimated using the Bayesian Maximum Entropy (BME)-based spatiotemporal modeling approach, integrating nationwide monitoring data from both the US Environmental Protection Agency (EPA) Air Quality System (AQS) and the output of chemical transport models, entitled Community Multiscale Air Quality (Reyes et al., 2017). Our empirical data showed that the BME estimates of daily PM$_{2.5}$ exposures correlated well with recorded concentrations from the AQS (average cross-validation Pearson’s R$^2$=0.70). The statistically-validated BME model was then applied to each geocoded residential location, accounting for residential mobility in 1999-2010, and exposure estimates were then aggregated to represent the average PM$_{2.5}$ 3-years preceding the first MRI scan. See Supplementary Methods for more details.

**Covariate data**

A structured questionnaire was administered to participants at WHIMS enrollment to gather information on demographics (e.g., age; race/ethnicity [Black/African-American; Hispanic White; non-Hispanic White; other/missing]), socioeconomic factors (e.g., education [< high school; high school/GED; > high school]; family income [< $10,000; $10,000-$34,999; $35,000-$74,999; ≥ $75,000]; employment status [currently employed; not working; retired]), and lifestyle factors (e.g., smoking status [never smoked; past smoker; current smoker]; alcohol intake [non-drinker; past drinker; < 1 drink per day; > 1 drink per day]; physical activity [no activity; some activity; 2-4 episodes per week; > 4 episodes per week). Additionally, clinical characteristics were ascertained including any postmenopausal hormone treatment ever, history
of cardiovascular disease (including previous coronary heart disease [e.g., myocardial infarction, coronary angioplasty, or coronary artery bypass graft], stroke, or transient ischemic attack), hypertension (defined as elevated blood pressure [systolic ≥140 or diastolic ≥90 mmHg], or use of antihypertensive medication), and diabetes mellitus (defined as physician diagnosis plus oral medications, or insulin therapy). Good reliability and validity of both the self-reported medical histories and the physical measures have been previously documented (Heckbert et al., 2004; Johnson-Kozlow et al., 2007; Margolis et al., 2008).

**Statistical analysis**

We constructed multilevel structural equation models (SEM) to characterize the longitudinal trajectory of each CVLT measure and examined the respective association with PM$_{2.5}$ exposure. Years across repeated CVLT assessments were used as the time-scale, centered on the individual-specific date of the first MRI (MRI-1). The average trajectories of CVLT performance were assumed to follow piecewise-linear declines joined at MRI-1. The multilevel SEM allowed for one random intercept (representing CVLT performance at MRI-1) and two random slopes (individual-specific linear changes before and after the MRI-1), while accounting for the practice effect and the use of two CVLT forms, as defined in the within-individual portion of SEM (Equation 1, Supplementary Methods). These individual-specific parameters of individual trajectories were entered into the between-individual portion of the multilevel SEM to assess the associations between PM$_{2.5}$ exposure and linear change in CVLT. To ensure the appropriate temporal relations between PM$_{2.5}$ and identified CVLT trajectories, the relevant exposure time window was defined as 3 years preceding the MRI-1, with the resulting effect on annual rate of CVLT change after MRI-1. The between-individual portion of the fully adjusted multilevel SEM is depicted in panel A of Fig. 2 and in the Supplemental methods. Separate SEMs were run for each CVLT measure and composite score.

The estimated PM$_{2.5}$ exposure effects on CVLT performance at MRI-1 and change post MRI-1 were all adjusted for the following covariates: age at MRI-1, race/ethnicity, geographic region of residence, education, household income, employment status, lifestyle factors (smoking; alcohol use; physical activities), and clinical characteristics (any prior hormone use ever, hypercholesterolemia, hypertension, diabetes, and history of cardiovascular disease).
We utilized multilevel SEMs with parallel-process mediation (Cheong et al., 2003) to assess whether increased AD-PS scores mediated the adverse PM$_{2.5}$ effects, if any observed on the post MRI-1 decline in CVLT performance. Panel B of Fig. 2 depicts the between-individual portion of the fully adjusted parallel process mediation SEM. AD-PS scores at MRI-1 and average annual changes in AD-PS ([AD-PS$_{MRI2}$ – AD-PS$_{MRI1}$]/years between MRI assessments) were added as variables to the between-individual portion of the multilevel model. The indirect effect, defined as the extent to which change in AD-PS score mediated the PM$_{2.5}$ effect on CVLT change, was estimated by adding two SEM paths: 1) the effect of PM$_{2.5}$ on change in AD-PS score; and 2) the effect of change in AD-PS score on change in CVLT. We then estimated the direct effect of PM$_{2.5}$ on CVLT change, defined as the PM$_{2.5}$ exposure effects on post MRI-1 change in CVLT performance, independent of change in AD-PS score. Using the approach described by Cheong, MacKinnon, and Khoo (2003) and Mackinnon et al. (2002), we estimated the proportion of the total PM$_{2.5}$ effect (the sum of the direct and indirect effect) on CVLT change that was mediated by changes in AD-PS score. In fully-adjusted multilevel parallel-process mediation SEMs, the PM$_{2.5}$ effects on the outcome variables (CVLT performance at MRI-1; annual change post MRI-1) and the putative mediators (AD-PS score at MRI-1 and subsequent change in AD-PS score) were all adjusted for the same set of covariates as described in the multilevel SEM models examining the PM$_{2.5}$ effect on CVLT trajectories.

Several additional analyses were conducted to examine the robustness of our findings. To assess the possible confounding by neighborhood socioeconomic characteristics, the SEMs further adjusted for census track-level socioeconomic characteristics of residential neighborhood (Qi et al., 2012) closest to MRI-1 (Supplementary Methods). To explore whether any observed associations between PM$_{2.5}$ and CVLT decline simply reflect the underlying dementia risk, we repeated our analyses after excluding incident dementia cases by 2010. To explore whether any observed associations could be explained by cerebrovascular disease and associated damage, we excluded incident stroke cases by 2010 (Supplementary Methods) and further adjusted for global SVID volume in the mediation analyses. We also conducted ad hoc mediation analyses by replacing the AD-PS score with global grey matter volume, to illustrate whether the associations between PM$_{2.5}$ and CVLT decline may be mediated by standard volumetric measures of global...
grey matter atrophy. To assess the possible unmeasured confounding by other factors that may operate through affecting the pre-MRI trajectories, we ran a sensitivity analysis allowing the correlation between exposure and the change in CVLT performance before MRI-1. Lastly, to ensure we were not overfitting the covariate structure, we constructed an alternative SEM where the estimated PM$_{2.5}$ effect on the post MRI-1 trajectory was only adjusted for the selected covariates significantly associated with changes in CVLT performance after MRI-1. All analyses were performed using MPLUS version 8 (Muthén and Muthén, 1998–2018) via the MPLUS automation package (Hallquist and Wiley, 2018) in R version 3.5.1.

**Data availability**

Access to all data elements used in this study may be made available following the established WHI policies.

**Results**

**Population characteristics**

The majority of these older women were Caucasian (92.0%) and had more than a high-school education (75.4%). Table 1 compares the distribution of the 3-year average PM$_{2.5}$ exposure prior to MRI-1, stratified by population characteristics. Participants exposed to higher levels of PM$_{2.5}$ were more likely to self-identify as African-American or Hispanic, reside in the West, and report higher household incomes ($\geq$75,000). Our study sample (n = 998) and the excluded subjects (n = 367) did not significantly differ by race/ethnicity, employment status, household income, smoking status, alcohol use, or selected clinical characteristics including hypertension, diabetes, or cardiovascular disease (Supplementary Table 1). Compared to women from the WHIMS-MRI cohort who were excluded from our final analytic sample, subjects included in our analyses were more likely to reside in the Midwest ($P < 0.01$), were more educated ($P < 0.01$), and reported more physical activities ($P = 0.02$), and also tended to have high cholesterol ($P = 0.07$) and use hormone treatment ($P = 0.06$). We also compared the population characteristics of our final sample (n = 998) by those who did (n = 531) and did not (n = 467) return for their second MRI scan (Supplementary Table 1). Compared to women who did not return, MRI-2 participants were
more likely to reside in the Midwest and Northeast regions ($P < 0.01$) and self-identify as non-Hispanic White ($P = 0.01$), but were less likely to report having hypertension ($P = 0.02$).

**Associations between PM$_{2.5}$ exposure and change in CVLT**

Multilevel SEMs revealed significant linear declines in episodic memory before MRI-1 across all CVLT measures (Supplementary Table 2 with estimated population trajectories). Linear declines in CVLT performance were generally larger after the MRI-1 across all measures except for long-delay free recall. The observed between-individual variability was statistically significant for the level of CVLT performance at the MRI-1 and linear changes in individual-specific estimates of all CVLT trajectories before MRI-1. Between-individual variability in change was generally larger after the MRI-1 but not statistically significant.

Across all CVLT measures, PM$_{2.5}$ exposure was not associated with the estimated level of performance at MRI-1 (Table 2, upper panel). There was evidence for adverse PM$_{2.5}$ effects with greater declines in both CVLT measures of immediate recall and new learning (List A learning trials 1-3 and List B learning/recall trial), but no statistically significant associations were found with delayed-recalls or composite measure (Table 2, lower panel). Across each inter-quartile increment of PM$_{2.5}$ (2.81 μg/m$^3$), the average rate of annual decline in immediate recall/new learning was significantly accelerated by 0.040 SDs (95% CI: -0.076, -0.004) for Trials 1-3 and 0.057 SDs (-0.096, -0.017) for List B. As compared with the effect of age at MRI-1 ($\beta_{\text{age}} = -.010$; $P = 0.017$) in the same model on post MRI-1 change in CVLT trials 1-3, the magnitude of the adverse exposure effect (per inter-quartile increment of PM$_{2.5}$) was equivalent to approximately four years of accelerated decline in immediate recall/new learning performance. Overall, the multicovariate-adjusted average rate of change was significantly accelerated by 19.3% (95% CI = 1.9%, 36.2%) for Trials 1-3 and 14.8% (4.4%, 24.9%) for List B.

**Mediation analyses involving AD-PS scores**

The results of the multilevel SEMs with parallel process mediation are presented in Table 3. PM$_{2.5}$ exposure was associated with an increased AD-PS score ($\beta_{\text{PM2.5 on } \Delta\text{AD-PS}} = .018; .001, .034$). Increases in the AD-PS score were also associated with greater declines on both Trials 1-3 ($\beta_{\Delta\text{AD-PS on Trials 1-3 post-MRI change}} = -.459; -.804, -.115$) and List B ($\beta_{\Delta\text{AD-PS on List B post-MRI change}} = -$
For Peer Review

.347; -.609, -.085) performance after MRI-1. The multicovariate-adjusted indirect PM$_{2.5}$ effects on post MRI-1 changes were statistically significant for both Trials 1-3 (Indirect PM$_{2.5}$ on Trials 1-3 post-MRI change = -.008; -.0262, -.0002) and List B performance (Indirect PM$_{2.5}$ on List B post-MRI change = -.006; -.0170, -.0002). Together, the estimated change in AD-PS significantly mediated the observed association between PM$_{2.5}$ exposure and post MRI-1 declines of both Trials 1-3 and List B performance. In fully-adjusted models, the mediation path that linked PM$_{2.5}$ exposure with accelerated declines of episodic memory by increasing the AD-PS score explained 22.6% (1.0% - 68.9%) and 10.7% (1.0% - 30.3%) of the adverse effects on CVLT performance in Trials 1-3 and List B performance, respectively.

**Sensitivity analyses**

In the analysis further adjusting for census track-level socioeconomic characteristics of residential neighborhood, the findings were robust (Supplementary Tables 3 and 4). After excluding 31 older women with incident dementia, the association with CVLT decline in Trials 1-3 was modestly attenuated and became marginally significant (p=0.056), but the corresponding association with CVLT decline in List B performance remained statistically significant (Supplementary Table 5). Importantly, excluding the incident dementia cases only caused minimal changes to the results on mediation by increased AD-PS scores (Supplementary Table 6). Furthermore, the overall patterns of observed associations, including the estimates of adverse PM$_{2.5}$ effect and results of mediation analyses, were robust after excluding 17 women with incident clinical stroke by 2010 and further adjusting for global SVID (Supplementary Tables 7 and 8). When the change in total grey matter volume was assumed as a mediator of PM$_{2.5}$ effect on changes in CVLT performance, we found the direct PM$_{2.5}$ effects on decline of immediate recalls/new learning remained statistically significant, but global change in grey matter did not play any significant role in mediating the observed associations (Supplementary Table 9). Lastly, allowing CVLT change before MRI-1 to covary with PM$_{2.5}$ exposure (Supplementary Tables 10 and 11) or regressing change after MRI-1 only on selected covariates (age at MRI-1; geographic region of residence; household income) predictive of the post MRI-1 trajectories (Supplementary Tables 12 and 13) did not have any notable impacts on the results.

**Discussion**
In this prospective study on older women, our findings suggest that long-term exposure to ambient PM$_{2.5}$ at residential locations was associated with accelerated declines in episodic memory, specifically in the measures of immediate recalls and new learning. Using a parallel-process SEM approach, we further demonstrated that the PM$_{2.5}$-associated greater decline in episodic memory (immediate recall and new learning) was partly (10-22%) mediated by increasing AD-PS scores – a structural brain MRI-based neuroanatomic biomarker reflecting high-dimensional gray matter atrophies in brain areas vulnerable to Alzheimer’s disease neuropathology. These observed associations could not be explained by socio-demographic factors (age; geographic region; race/ethnicity; education; income), lifestyle (smoking; alcohol; physical activity), employment status, clinical characteristics (diabetes; high cholesterol; hypertension; cardiovascular diseases; hormone therapy), or MRI-measured cerebrovascular diseases, and remained measurable after excluding incident cases of dementia and stroke. In contrast, we found no evidence of statistically significant associations between PM$_{2.5}$ exposure and the observed declines in delayed-recall or the composite measure of episodic memory. To our knowledge, this is the first study to suggest that long-term PM$_{2.5}$ exposure accelerates the early cognitive decline commonly seen before the dementia onset, and this putative neurotoxic effect in the preclinical stage is mediated by altered brain structure that predicts subsequent Alzheimer’s disease risk.

Previous studies on air pollution and cognitive decline had yielded inconsistent results (Peters et al., 2019), but our data provide the most compelling epidemiologic evidence so far to support the adverse effect on the preclinical trajectories of episodic memory in older women affected by PM$_{2.5}$ exposure in late life, suggesting the long-term air pollution neurotoxicity across the Alzheimer’s disease continuum. Episodic memory is one of the cognitive domains with early declines detectable in preclinical Alzheimer’s disease (Aisen et al., 2017). Three cohort studies had examined the association between PM$_{2.5}$ exposure and episodic memory decline, but their reported findings were mixed, including no significant association in the Nurses’ Health Study (Weuve et al., 2012), a positive association in the Boston Puerto Rican Health Study (Wurth et al., 2018) and a negative association (with a single measure of immediate recall) in the Whitehall II study (Tonne et al., 2014). These three reports were limited by only 2-3 cognitive assessments,
and so far none of these cohort studies had examined the association between exposure and incident dementia or clinically significant cognitive impairment. Investigators in the Betula Project in Sweden possibly made the first attempt to establish the air pollution exposure effect continuum in dementia. They found nitrogen oxide exposure was associated with increased dementia risk (Oudin et al., 2016), but not with episodic memory decline (Oudin et al., 2017). The exact reasons for this discrepancy were unclear, because episodic memory measured 10 years prior to clinical diagnosis significantly predicted dementia in the Betula cohort (Boraxbekk et al., 2015). One possible explanation is that the air pollution neurotoxicity observed in the Swedish cohort only accelerated the pathological brain aging process during the clinical stage. However, this interesting hypothesis was not supported by the neurotoxicological data showing that diesel engine exhaust accelerated amyloid-β plaque formation, with no overt deficits in spatial memory (Hullmann et al., 2017). In contrast, we had previously reported that residing in locations with high PM$_{2.5}$ exposure was associated with clinically significant cognitive impairment and dementia among non-Hispanic white older women WHIMS (Cacciottolo et al., 2017). In the current study using data from WHIMS participants who were tested with CVLT annually for the WHISCA, we further found that PM$_{2.5}$ exposure was associated with greater declines in episodic memory (immediate recall and new learning), equivalent to approximately 4 years of accelerated decline. These findings were observed even among cognitively intact older women without dementia. We also showed these observed adverse PM$_{2.5}$ effects on accelerated decline in episodic memory were partly mediated by the increased AD-PS score, an earlier biomarker reflecting the neuroanatomic risk associated with reflecting progressive grey matter atrophy in brain regions vulnerable to Alzheimer’s disease neuropathology. Although our collective findings point to the possible continuum of PM$_{2.5}$ neurotoxicity across the early neuropsychological processes and altered brain structures predictive of subsequent dementia risk, we call for future studies to replicate our results in other populations and to further substantiate the scientific evidence of the continuum of air pollution neurotoxicity in the preclinical stage.

Our study illustrates the promise of new approaches to better understanding the neuropsychological processes and altered brain structure associated with air pollution exposure. First, to the best of our knowledge, this was the first air pollution epidemiologic study to combine both longitudinal brain MRI and cognitive function data, allowing us to investigate the
brain-behavior relations affected by PM$_{2.5}$ neurotoxicity. Such combined neuroimaging-neuropsychological data analyses are important as they better inform our understanding of the brain determinants of the cognitive changes of Alzheimer’s disease to address important clinical and scientific challenges presented by Alzheimer’s disease (Mungas et al., 2012). Second, using a sophisticated parallel-process SEM, our study represents the first application to air pollution epidemiology of brain aging to simultaneously model level and change in both cognitive decline and longitudinal change in structural brain MRI measures and further examine the hypothesized mediation effects. This analytic approach is important because it allows researchers to directly examine complex questions about intra-individual changes in cognitive performance and neuroimaging data in a single statistical model. Lastly, we used the AD-PS scores as a more specific measure of altered brain structure in brain areas that are likely more vulnerable to the Alzheimer’s disease neurodegenerative processes. In contrast, previous human studies using neuroimaging data to investigate the PM$_{2.5}$-effects on altered brain structure used the region-of-interest approach (Chen et al., 2015; Wilker et al., 2015; Power et al., 2018) or conducted whole-brain analyses (Casanova et al., 2016), and neither none of these studies found a significant association with the volumes of hippocampus, which is not specific to Alzheimer’s disease (Frisoni et al., 2010). Also, the majority of these previous studies (Chen et al., 2015; Wilker et al., 2015; Casanova et al., 2016) ignored did not evaluate the possibility that PM$_{2.5}$ neurotoxicity may result in brain atrophy with unique spatial patterns, similar to the spreading of neurodegenerative proteins as shown in many neuropathological studies in Alzheimer’s disease (Brettschneider et al., 2015). Although Power et al. (2018) also studied gray-matter volumes in brain regions vulnerable to Alzheimer’s disease neuropathology, a few methodological differences were noteworthy. For instance, Power et al. investigated the putative neurotoxic effects of PM$_{2.5}$ on brain volumes measured at one time point, while we conducted a longitudinal study based on changes of AD-PS score across two time points (2005-6; 2010-11). Additionally, the “Alzheimer’s disease signature regions” utilized by Power et al. were selected based on work by Dickerson et al. (2011) applying a hypothesis-driven region-of-interest approach. In contrast, to create the AD-PS score, we took a data-driven approach using supervised machine learning based on a large-scale regularization algorithm that analyzes whole-brain gray matter tissue at the voxel-level and identifies the unique spatial patterns of localized gray matter atrophy in Alzheimer’s disease.
Our empirical data pointed to the possibility that PM$_{2.5}$ neurotoxicity may have differential effects across the episodic memory processes, although the biological underpinnings of such observed differences are unclear. Published work on PM$_{2.5}$ and episodic memory decline had found an unexpected positive association in the Boston Puerto Rican Health Study (Wurth et al., 2018) and no statistically significant association in the Nurses’ Health Study (Weuve et al., 2012), both using a composite measure, which ignores the important heterogeneity in the neuropsychological processes that comprise episodic memory performance. In the present study, we were able to show the differential effects of PM$_{2.5}$ exposure on episodic memory, with the exposure-associated decline predominantly affecting immediate recall and new learning and no significant association with delayed-recall ability or our composite measure of episodic memory. In the Baltimore Longitudinal Study of Aging, declines in CVLT immediate recall/encoding processes were observed first with Alzheimer’s disease progression, followed by changes in long-delayed free recall scores, suggesting that changes in immediate recall/new learning may take place earlier during the preclinical stages of Alzheimer’s disease (Bilgel et al., 2014). Thus, the observation of differential exposure effects on CVLT measures reinforces the suggestion that our study was capturing the PM$_{2.5}$ neurotoxic effects on the early neuropsychological processes of episodic memory decline at the preclinical stage. The medial temporal lobe and the interactions of its structural components play a central role in the episodic memory (Dickerson and Eichenbaum, 2010). Early studies have documented the functional specification of the prefrontal cortex involved in different cognitive processes in episodic memory (Fletcher et al., 1998a; Fletcher et al., 1998b). More recent studies further demonstrated the distinctive roles of large-scale cortical networks contributing to the different cognitive processes of episodic memory in individuals with prodromal (Putcha et al., 2019) and clinical Alzheimer’s disease (Wolk et al., 2011). Future studies need to continue examining the possibly differential exposure effects on the episodic memory processes and further elucidate how these related neural networks are affected by PM$_{2.5}$ neurotoxicity.

Our study results, as well as the growing literature on air pollution neurotoxicity, point to several important directions for advancing the environmental neurosciences of brain aging associated with exposure to ambient particles. We found that long-term PM$_{2.5}$ exposure was associated with
increasing AD-PS scores, which only accounted for 10-22% the PM$_{2.5}$-associated greater decline in episodic memory, and the direct exposure effects remained statistically significant (Table 3). Other contributors to the observed episodic memory decline associated with PM$_{2.5}$ exposure may include the alteration of other brain structures, changes in neural networks, and specific neuropathological processes, not fully captured by the increased AD-PS scores. For example, hippocampal subfields may be critical targets of the air pollution neurotoxicity on the neuropsychological processes of episodic memory decline. The medial temporal lobe and its structural components (especially the hippocampus) play a central role in encoding (learning; recall) and retrieving (recall) details of events that compose episodic memories (Dickerson and Eichenbaum, 2010). Although the roles of hippocampal subfields (e.g., cornu ammonis [CA, CA2-3]; CA4-denate gyrus; presubiculum; subiculum) on these distinct processes (encoding; retrieval) remain to be delineated, animal studies have demonstrated the adverse effects of PM and its constituents on morphological and functional changes within hippocampal subfields. For instance, decreased apical dendritic spine density and dendritic branches in the CA1 and CA3 regions (Fonken et al., 2011), reduced synaptic function (Ku et al., 2017) in CA1 neurons (Davis et al., 2013), and decreased myelin basic protein in white matter and increased atrophy of neurites in the CA1 region (Woodward et al., 2017) have been observed. These neurotoxicological data collectively suggest that some hippocampal subfields may be more sensitive than others to the adverse PM-effects. Additionally, human imaging studies (Zhao et al., 2019) have found that atrophy in hippocampal subfields imposed varying degrees of influences on different measures of episodic memory (immediate recalls; delayed-recalls; recognition). Previous research also suggests that the CA2, CA3, and dentate gyrus are responsible for encoding, while the CA1 and subiculum are responsible for retrieval (Zammit et al., 2017). Our findings of significant declines predominantly in immediate recall/new learning imply that the adverse PM$_{2.5}$ effects on episodic memory processes may be more targeted towards hippocampal subfields related to encoding, such as the CA2, CA3, and dentate gyrus. High-resolution neuroimaging studies are needed to determine whether there is indeed a subfield neurotoxicity involved. Next, studies have shown that cerebrovascular disease, MRI measures of vascular brain injury (e.g., white matter hyperintensities; infarcts), and vascular risk factors are independently associated with cognitive decline (Marchant et al., 2013; DeCarli et al., 2019). Our exploratory analyses showed robust findings even after further adjustment for global SVID.
volume (a proxy for cerebrovascular damage) or excluding women with incident clinical stroke. Although these results suggest that the observed mediation by increased AD-PS score associated with late-life exposure to PM$_{2.5}$ may be independent of large-vessel diseases or global cerebrovascular damage, it is important not to rule out other measures of cerebral small-vessel diseases (e.g., microbleeds; cerebral amyloid angiopathy) for their potential contributions to the exposure effects on episodic memory declines. Lastly, other neuropathological processes underlying the observed mediation by increasing AD-PS scores are unclear. Meta-analyses of studies with PET scans of cognitively-normal individuals found that high amyloid-β status predicts subsequent decline in episodic memory (Baker et al., 2017). PET studies have also shown that grey matter atrophy may be a consequence of tau neuropathological processes, which in turn may be driving the observed cognitive decline (Bejanin et al., 2017; Jagust, 2018; Harrison et al., 2019). Future neuroimaging studies are needed to determine whether specific neuropathological processes (e.g., aggregation of phosphorylated tau in neurofibrillary tangles; amyloid-β plaque deposition) drive the PM$_{2.5}$-associated greater decline in episodic memory.

We recognize several limitations of our study. First, although the BME spatiotemporal models were well cross-validated (average Pearson’s R$^2$=0.70) to estimate PM$_{2.5}$ exposures, these resulting estimates were still subject to measurement errors because individual-level data on time-activity patterns of our study participants were not available. However, such estimation errors tend to be non-differential, most likely resulting in attenuation of the observed associations. Second, we were unable to estimate early- or mid-life PM$_{2.5}$ exposures, because nationwide PM$_{2.5}$ monitoring data were unavailable prior to 1999 and early-life residential location data were not collected in WHI. Since air pollution levels have been declining over the past two decades, early- or mid-life PM$_{2.5}$ exposure effects could have been greater than or different from what we observed in our study on late-life exposure. Third, our study focused on regional PM$_{2.5}$ only, and we did not investigate its chemical constituents (e.g., black carbon; inorganic secondary aerosols), other exposure sources (e.g., from near-roadways), or possible interactions with other pollutant mixtures (e.g., with photochemical reactions of gaseous pollutants). Fourth, although our sensitivity analyses suggest stroke and cerebrovascular disease damage could not explain the observed adverse PM$_{2.5}$ effects on episodic memory decline, we did not examine multiple mediation pathways involving longitudinal SVID changes. Extant
literature on air pollution neuroimaging studies do not support the association between late-life exposure to air pollution and MRI-measured cerebrovascular damage (Chen et al., 2015; Wilker et al., 2015; Wilker et al., 2016; Kulick et al., 2017; Power et al., 2018), but it remains possible that PM$_{2.5}$ exposures before late-life could impart adverse effects that we may have missed in the current study. Fifth, we could not completely rule out the possibility of unmeasured confounding by other environmental factors (e.g., outdoor noise; neighborhood green space) that may be correlated with PM$_{2.5}$. However, the extant epidemiologic data do not provide strong evidence for these environmental factors to accelerate episodic memory decline at the preclinical stage; therefore, their role as potential confounders is not well-established. Lastly, our findings may not be generalizable to men or younger women.

This study also had several major strengths. First, women were prospectively followed over a long period of time (~11 years), with annual assessments of both their immediate- and delayed-recall, allowing us to examine whether of PM$_{2.5}$-exposure was differentially associated with these cognitive processes. Second, we employed the sophisticated parallel-process mediation SEM approach, which allowed us to examine whether PM$_{2.5}$ effects level and change of episodic memory performance, while also investigating to what extent AD-PS scores may mediate this association. Third, our AD-PS scores were able to capture the spatial patterns of brain tissue atrophy more specific to Alzheimer’s disease. Lastly, the rich, comprehensive data of the geographically diverse WHIMS cohort allowed us to adjust for potential confounding by multiple covariates and address other sources of biases.

In summary, this study provided the first epidemiological evidence suggesting long-term PM$_{2.5}$ exposure in late life is associated with accelerated decline of episodic memory, predominantly affecting immediate recall and new learning. Increases in neuroanatomical risk for Alzheimer’s disease associated with PM$_{2.5}$ partially explained these negative associations. The adverse effects remained measurable even after excluding incident dementia, suggesting the possible continuum of PM$_{2.5}$ neurotoxicity that may contribute to early decline of immediate recall and new learning abilities at the preclinical stage. Because this is the first study of its kind combining both longitudinal data on cognitive decline and a neuroanatomic risk score for Alzheimer’s disease, replication of our findings will be needed to substantiate the suggestion for continuum of air
pollution neurotoxicity. Future neuroimaging studies are needed to further explore the links between episodic memory processes and altered brain structures, especially hippocampal subfields and other related neural networks, underpinning the observed association between PM$_{2.5}$ and dementia risk.
Acknowledgements

The investigators appreciate Dr. Eric Whitsel for assisting in post-estimation data processing and delivering of pollution exposure data and neighborhood contextual data used in this study.

Funding

The results reported herein correspond to the specific aims of R01ES025888 from the National Institute of Environmental Health Sciences. The air pollution exposure data were derived from the R01AG033078 (PI: JC) and the AD-PS score data were generated from R21AG051113 (PI: Casanova and Chen), both supported by the National Institute on Aging. This work is also supported by R01AG033078 (PI: JC) and RF1AG054068 (PI: JC). Drs. Younan, Petkus, Wang, Espeland and Chen are also supported by RF1AG054068 (PI: Chen). Research work of Drs. Younan and Chen are also supported by the Southern California Environmental Health Sciences Center (5P30ES007048). Dr. Chui is supported by P50AG05142. Drs. Casanova, Espeland, and Rapp receive funding from the Wake Forest Alzheimer’s Disease Core Center (P30AG049638–01A1). Dr. Resnick is supported by the Intramural Research Program, National Institute on Aging, NIH. Dr. Henderson is supported by P50AG047366. The WHI programs is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts, HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C and HHSN271201100004C. For a list of all the investigators who have contributed to WHI science, please visit:


The Women’s Health Initiative Memory Study was funded as an ancillary study to the WHI by Wyeth Pharmaceuticals, Inc., Wake Forest University; and the National Heart, Lung, and Blood Institute, National Institutes of Health; and the National Institute of Aging, National Institutes of Health (contract number HHSN271-2011-0004C). The Women's Health Initiative Magnetic Resonance Imaging Study was funded by contract N01-WH-44221, from the National Heart, Lung, and Blood Institute.

Competing interests

The authors report no competing interests.
References


Table 1
Comparison of estimated PM$_{2.5}$ exposure measured at MRI-1 visit by baseline population characteristics (N = 998)

<table>
<thead>
<tr>
<th>Population Characteristics</th>
<th>N (%)</th>
<th>Mean</th>
<th>SD</th>
<th>25$^{th}$</th>
<th>Median</th>
<th>75$^{th}$</th>
<th>p$^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>998</td>
<td>11.63</td>
<td>2.41</td>
<td>10.1</td>
<td>10.8</td>
<td>13.0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Region of Residence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Northeast</td>
<td>174 (17.4)</td>
<td>11.62</td>
<td>1.36</td>
<td>10.7</td>
<td>11.2</td>
<td>12.6</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>South</td>
<td>156 (15.6)</td>
<td>10.98</td>
<td>1.42</td>
<td>9.8</td>
<td>10.2</td>
<td>12.3</td>
<td></td>
</tr>
<tr>
<td>Midwest</td>
<td>398 (39.9)</td>
<td>11.53</td>
<td>2.10</td>
<td>10.2</td>
<td>10.5</td>
<td>14.0</td>
<td></td>
</tr>
<tr>
<td>West</td>
<td>270 (27.1)</td>
<td>12.16</td>
<td>3.47</td>
<td>10.1</td>
<td>10.8</td>
<td>14.5</td>
<td></td>
</tr>
<tr>
<td>Race/Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>African-American</td>
<td>42 (4.2)</td>
<td>13.44</td>
<td>2.59</td>
<td>12.0</td>
<td>13.0</td>
<td>14.3</td>
<td></td>
</tr>
<tr>
<td>Hispanic White</td>
<td>13 (1.3)</td>
<td>12.34</td>
<td>2.38</td>
<td>10.6</td>
<td>11.5</td>
<td>13.7</td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>918 (92)</td>
<td>11.52</td>
<td>2.33</td>
<td>10.1</td>
<td>10.7</td>
<td>12.6</td>
<td></td>
</tr>
<tr>
<td>Other or Missing</td>
<td>25 (2.5)</td>
<td>12.13</td>
<td>3.44</td>
<td>10.2</td>
<td>11.3</td>
<td>12.7</td>
<td></td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.05</td>
</tr>
<tr>
<td>Less than high school</td>
<td>36 (3.6)</td>
<td>11.62</td>
<td>2.25</td>
<td>10.4</td>
<td>11.2</td>
<td>13.5</td>
<td></td>
</tr>
<tr>
<td>High school</td>
<td>210 (21)</td>
<td>11.27</td>
<td>1.96</td>
<td>10.1</td>
<td>10.6</td>
<td>11.6</td>
<td></td>
</tr>
<tr>
<td>More than high school</td>
<td>752 (75.4)</td>
<td>11.73</td>
<td>2.52</td>
<td>10.1</td>
<td>10.8</td>
<td>13.2</td>
<td></td>
</tr>
<tr>
<td>Employment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.28</td>
</tr>
<tr>
<td>Currently working</td>
<td>185 (18.5)</td>
<td>11.40</td>
<td>2.53</td>
<td>10.1</td>
<td>10.6</td>
<td>12.3</td>
<td></td>
</tr>
<tr>
<td>Not working</td>
<td>99 (9.9)</td>
<td>11.84</td>
<td>2.33</td>
<td>10.2</td>
<td>10.9</td>
<td>13.4</td>
<td></td>
</tr>
<tr>
<td>Retired</td>
<td>714 (71.5)</td>
<td>11.66</td>
<td>2.38</td>
<td>10.1</td>
<td>10.8</td>
<td>13.0</td>
<td></td>
</tr>
<tr>
<td>Income (in USD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td>&lt; 9,999</td>
<td>198 (19.8)</td>
<td>11.29</td>
<td>2.05</td>
<td>10.2</td>
<td>10.7</td>
<td>11.8</td>
<td></td>
</tr>
<tr>
<td>10,000-34,999</td>
<td>299 (30)</td>
<td>11.59</td>
<td>2.38</td>
<td>10.0</td>
<td>10.7</td>
<td>13.0</td>
<td></td>
</tr>
<tr>
<td>35,000-49,999</td>
<td>230 (23)</td>
<td>11.62</td>
<td>2.40</td>
<td>10.1</td>
<td>10.7</td>
<td>12.8</td>
<td></td>
</tr>
<tr>
<td>50,000-74,999</td>
<td>141 (14.1)</td>
<td>11.77</td>
<td>2.64</td>
<td>10.2</td>
<td>10.9</td>
<td>13.2</td>
<td></td>
</tr>
<tr>
<td>75,000 or more</td>
<td>100 (10)</td>
<td>12.28</td>
<td>2.71</td>
<td>10.4</td>
<td>11.0</td>
<td>14.5</td>
<td></td>
</tr>
<tr>
<td>Don’t know</td>
<td>30 (3)</td>
<td>11.59</td>
<td>2.41</td>
<td>10.1</td>
<td>11.1</td>
<td>13.2</td>
<td></td>
</tr>
<tr>
<td>Lifestyle</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.26</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoked</td>
<td>584 (58.5)</td>
<td>11.67</td>
<td>2.42</td>
<td>10.2</td>
<td>10.8</td>
<td>13.0</td>
<td></td>
</tr>
<tr>
<td>Past smoker</td>
<td>376 (37.7)</td>
<td>11.52</td>
<td>2.34</td>
<td>10.1</td>
<td>10.7</td>
<td>12.6</td>
<td></td>
</tr>
<tr>
<td>Current Smoker</td>
<td>38 (3.8)</td>
<td>12.14</td>
<td>2.72</td>
<td>10.1</td>
<td>11.1</td>
<td>14.1</td>
<td></td>
</tr>
<tr>
<td>Alcohol use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.30</td>
</tr>
<tr>
<td>Non-drinker</td>
<td>131 (13.1)</td>
<td>11.85</td>
<td>2.46</td>
<td>10.1</td>
<td>11.0</td>
<td>13.5</td>
<td></td>
</tr>
<tr>
<td>Past drinker</td>
<td>157 (15.7)</td>
<td>11.56</td>
<td>2.23</td>
<td>10.1</td>
<td>10.7</td>
<td>13.0</td>
<td></td>
</tr>
<tr>
<td>Less than 1 drink per day</td>
<td>596 (59.7)</td>
<td>11.54</td>
<td>2.37</td>
<td>10.1</td>
<td>10.7</td>
<td>12.5</td>
<td></td>
</tr>
<tr>
<td>More than 1 drink per day</td>
<td>114 (11.4)</td>
<td>11.92</td>
<td>2.73</td>
<td>10.3</td>
<td>11.0</td>
<td>13.2</td>
<td></td>
</tr>
<tr>
<td>Moderate or strenuous activities ≥ 20 minutes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.15</td>
</tr>
<tr>
<td>No activity</td>
<td>547 (54.8)</td>
<td>11.66</td>
<td>2.44</td>
<td>10.1</td>
<td>10.8</td>
<td>13.2</td>
<td></td>
</tr>
<tr>
<td>Some activity</td>
<td>57 (5.7)</td>
<td>12.01</td>
<td>2.35</td>
<td>10.4</td>
<td>10.8</td>
<td>14.3</td>
<td></td>
</tr>
<tr>
<td>2-4 episodes/week</td>
<td>214 (21.4)</td>
<td>11.73</td>
<td>2.48</td>
<td>10.2</td>
<td>10.7</td>
<td>13.0</td>
<td></td>
</tr>
<tr>
<td>Physical Health</td>
<td>0.78</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>≥4 episodes/week</strong></td>
<td>180 (18)</td>
<td>11.30</td>
<td>2.18</td>
<td>10.0</td>
<td>10.8</td>
<td>12.2</td>
<td></td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>644 (64.5)</td>
<td>11.61</td>
<td>2.44</td>
<td>10.1</td>
<td>10.8</td>
<td>13.0</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>354 (35.5)</td>
<td>11.66</td>
<td>2.35</td>
<td>10.2</td>
<td>10.7</td>
<td>12.9</td>
<td></td>
</tr>
<tr>
<td><strong>High Cholesterol</strong></td>
<td>0.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>827 (82.9)</td>
<td>11.57</td>
<td>2.37</td>
<td>10.1</td>
<td>10.7</td>
<td>12.9</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>171 (17.1)</td>
<td>11.91</td>
<td>2.58</td>
<td>10.3</td>
<td>10.9</td>
<td>13.3</td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes Mellitus</strong></td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>969 (97.1)</td>
<td>11.64</td>
<td>2.43</td>
<td>10.1</td>
<td>10.7</td>
<td>13.0</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>29 (2.9)</td>
<td>11.41</td>
<td>1.33</td>
<td>10.6</td>
<td>10.9</td>
<td>12.3</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular disease</strong></td>
<td>0.39</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>857 (85.9)</td>
<td>11.60</td>
<td>2.41</td>
<td>10.1</td>
<td>10.8</td>
<td>12.8</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>141 (14.1)</td>
<td>11.79</td>
<td>2.40</td>
<td>10.2</td>
<td>10.7</td>
<td>13.7</td>
<td></td>
</tr>
<tr>
<td><strong>Hormone treatment ever</strong></td>
<td>0.77</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>520 (52.1)</td>
<td>11.61</td>
<td>2.28</td>
<td>10.2</td>
<td>10.7</td>
<td>12.9</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>478 (47.9)</td>
<td>11.65</td>
<td>2.53</td>
<td>10.1</td>
<td>10.8</td>
<td>13.0</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)PM\(_{2.5}\) represents the 3-year exposures aggregated from the daily exposure levels estimated at each residential location prior MRI-1 visit time using the Bayesian maximum entropy spatiotemporal model.

\(^b\)p values estimated from ANOVA tests comparing average exposure.
Table 2
Associations between 3-year average PM$_{2.5}$ (per inter-quartile range of 2.81 μg/m$^3$) exposure and estimated trajectories of CVLT performance

<table>
<thead>
<tr>
<th>CVLT Measures</th>
<th>Unadjusted</th>
<th>Fully-adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (95% CI)</td>
<td>β (95% CI)</td>
</tr>
<tr>
<td><strong>Estimates$^a$ of PM$_{2.5}$ effects on CVLT performance at MRI-1$^b$</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trials 1-3</td>
<td>.014 (-.043, .070)</td>
<td>.002 (-.052, .057)</td>
</tr>
<tr>
<td>List B</td>
<td>.045 (-.002, .091)</td>
<td>.041 (-.003, .084)</td>
</tr>
<tr>
<td>Short-delay free recall</td>
<td>-.011 (-.067, .028)</td>
<td>-.017 (-.071, .038)</td>
</tr>
<tr>
<td>Long-delay free recall</td>
<td>-.017 (-.073, .038)</td>
<td>-.026 (-.080, .029)</td>
</tr>
<tr>
<td>Composite score</td>
<td>-.008 (-.063, .046)</td>
<td>-.017 (-.070, .036)</td>
</tr>
<tr>
<td><strong>Estimates$^a$ of PM$_{2.5}$ effects on the annual change in CVLT performance after MRI-1$^c$</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trials 1-3</td>
<td>-.039 (-.075, -.004)</td>
<td>-.040 (-.076, -.004)</td>
</tr>
<tr>
<td>List B</td>
<td>-.053 (-.093, -.014)</td>
<td>-.057 (-.096, -.017)</td>
</tr>
<tr>
<td>Short-delay free recall</td>
<td>-.009 (-.046, .028)</td>
<td>-.007 (-.045, .031)</td>
</tr>
<tr>
<td>Long-delay free recall</td>
<td>-.006 (-.045, .033)</td>
<td>-.002 (-.041, .037)</td>
</tr>
<tr>
<td>Composite score</td>
<td>-.020 (-.052, .013)</td>
<td>-.018 (-.051, .015)</td>
</tr>
</tbody>
</table>

Abbreviations: CVLT = California Verbal Learning Test

Bolded estimates denote PM$_{2.5}$ effects that are statistically significant at p<.05

$^a$All estimates derived from the multilevel structural equation model (SEM) as depicted in Fig. 2 panel A.

$^b$Estimates correspond to the β$_{PM_{2.5}}$ on CVLT level parameter depicted in Fig. 2 panel A. In fully-adjusted models, the effect of PM$_{2.5}$ on CVLT performance at MRI-1 were adjusted for age at MRI-1, race/ethnicity, geographic region of residence, education, household income, employment status, lifestyle factors (smoking, alcohol use, physical activities) and clinical characteristics (use of hormone treatment; hypercholesterolemia, hypertension, diabetes, and history of cardiovascular disease).

$^c$Estimates correspond to the β$_{PM_{2.5}}$ on post-MRI change parameter depicted in Fig. 2 panel A. In fully-adjusted models, the effect of PM$_{2.5}$ on change in CVLT performance after MRI-1 was adjusted for age at MRI-1, race/ethnicity, geographic region of residence, education, household income, employment status, lifestyle factors (smoking, alcohol use, physical activities) and clinical characteristics (use of hormone treatment; hypercholesterolemia, hypertension, diabetes, and history of cardiovascular disease).
Table 3
Results of multilevel structural equation models with parallel process mediation to examine whether increased Alzheimer’s disease pattern similarity scores mediate the adverse PM$_{2.5}$ effects (per inter-quartile range of 2.81 μg/m$^3$) on declines of immediate recall/new learning

<table>
<thead>
<tr>
<th></th>
<th>CVLT Trials 1-3</th>
<th></th>
<th>CVLT List B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unadjusted β</td>
<td>Adjusted β</td>
<td>Unadjusted β</td>
</tr>
<tr>
<td></td>
<td>(95% CI)</td>
<td>(95% CI)</td>
<td>(95% CI)</td>
</tr>
<tr>
<td>Estimates$^a$ of Direct Effect</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effect of PM$_{2.5}$ on annual change in CVLT performance after MRI-1, accounting for the indirect effect$^b$</td>
<td>-.024</td>
<td>-.030</td>
<td>-.045</td>
</tr>
<tr>
<td></td>
<td>(-.059, .012)</td>
<td>(-.089, -.008)</td>
<td>(-.085, -.006)</td>
</tr>
</tbody>
</table>

| Estimates$^a$ of Indirect Effect |                      |                     |
| Effects of PM$_{2.5}$ on the increase of in AD-PS scores$^c$ | .022              | .018                | .022        | .018       |
|                      | (.006, .039)     | (.001, .034)        | (.006, .039) | (.001, .034) |
| Effects of increased AD-PS score on annual change in CVLT performance after MRI-1$^d$ | -.592             | -.459               | -.333       | -.347      |
|                      | (-.913, -.271)   | (-.804, -.115)      | (-.587, -.079) | (-.609, -.085) |

| Proportion of Total PM$_{2.5}$ Effect Mediated by Increased AD-PS Scores | 35.1% | 22.6% | 13.2% | 10.7% |
|                                                                        | (6.2%, 78.1%)    | (1%, 68.9%)        | (1.3%, 35.1%) | (1%, 30.3%) |

Abbreviations: AD-PS = Alzheimer’s disease pattern similarity score that was z-score standardized based on the mean and standard deviation at WHIMS MRI-1

All estimates bolded if statistically significant at p<.05

$^a$ All estimates derived from the multilevel structural equation models with parallel process mediation as depicted in panel B of Fig. 2. In fully-adjusted models, all the presented effect estimates on CVLT decline (direct PM$_{2.5}$ effects; indirect effect paths, including CVLT decline affected by increased AD-PS scores) were adjusted for age at MRI-1, race/ethnicity, attrition, geographic region of residence, education, household income, employment status, lifestyle factors (smoking, alcohol use, physical activities), and clinical characteristics (use of hormone treatment; hypercholesterolemia, hypertension, diabetes, and history of cardiovascular disease).
bEstimate corresponds to the $\beta_{PM2.5}$ on post-MRI change parameter depicted in panel B of Fig. 2.

cEstimate corresponds to the $\beta_{PM2.5}$ on $\Delta AD-PS$ parameter depicted in panel B of Fig. 2.

\textsuperscript{d}Estimate corresponds to the $\beta_{\Delta AD-PS}$ on post-MRI change parameter depicted in panel B of Fig. 2.
**Figure 1**
Flowchart for selection of final analytic sample

**Figure 2**
Panel A presents the portion of the fully adjusted multilevel structural equation model examining the associations between PM$_{2.5}$ exposure and level and change in CVLT performance. Panel B presents the parallel-process mediation structural equation model estimating the extent to which change in Alzheimer’s-Diseases Pattern Similarity score mediates the association between long-term fine particulate matter exposure and declines in episodic memory.